BioSpace News Archive

Drug Development

Cannabis-Derived MS Treatment Disappoints in Phase III Trial

The Phase III study of Jazz Pharmaceuticals cannabis-derived MS Sativex failed to achieve the primary endpoint of an improvement in muscle tone in patients.

June 29, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Axsome Advances MDD Drug, Explores New ADHD Treatment

Axsome hosted an investor day event to provide an update on plans for Sunosi and other developmental assets, including MDD treatment AXS-05.

June 29, 2022
·
2 min read
·
Alex Keown
Business

Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch

Although the company promised strong sales-based resources for the launch of dry eye drug Tyrvaya, the streamlining plan will include laying off up to 50 employees.

June 29, 2022
·
2 min read
·
Hannah Chudleigh
Drug Development

89bio Seeks $94.5M for Phase III SHTG Trial

89bio reported positive topline results from ENTRIGUE Phase II trial of pegozafermin in patients with severe hypertriglyceridemia.

June 29, 2022
·
2 min read
·
Alex Keown
Drug Development

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

CanariaBio Inc. announces that it has reached 50% of target enrollment of 602 patients for its pivotal Phase III clinical study of its lead product oregovomab, in combination with standard of care chemotherapy for the treatment of front-line advanced ovarian cancer patients.

June 29, 2022
·
3 min read
Santhera Updates on Ongoing NDA Submission for Vamorolone

Pratteln, Switzerland, June 29, 2022 – Santhera Pharmaceuticals announcesthat the clinical moduleof its rolling new drug application for vamorolone in Duchenne muscular dystrophy has been submitted to the U.S. Food and Drug Administration.

June 29, 2022
·
4 min read
Policy

Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen announced that the U.S. Food and Drug Administration has accepted for Priority Review its resubmitted New Drug Application for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder.

June 29, 2022
·
8 min read
Insulin Pumps Market Sustains Competitiveness by Adoption of Technological Innovations

Wilmington, Delaware, United States: The global insulin pumps market is anticipated to observe an abnormal state of rivalry among the key players in the market.

June 29, 2022
·
5 min read
Injectable Drug Delivery Market Insights [Size | Share | Trends] | Industry Outlook, 2031

The provision of maximum and quickest form of bioavailability of the administered drug continues to remain one of the key factors why injectable drug delivery continues to remain one of the most popular ways of administering drugs in patients across the globe.

June 29, 2022
·
8 min read
Expansion of Infection Surveillance Solutions Market Projected to be Supported by Significant Investment

Wilmington, Delaware, United States: The demand for infection surveillance has been on the rise as the need to curb hospital-acquired infections and other epidemics is intensifying.

June 29, 2022
·
5 min read